Based on these results, iTeos and GSK (GSK) have made the decision to terminate the belrestotug development program and end the collaboration. All belrestotug-containing cohorts are ending, and any new enrollment in the ongoing GALAXIES Lung-301 Phase 3 trial is ending. GSK is communicating with investigators, institutional review boards, ethics committees, and health authorities about next steps for appropriate management of currently enrolled patients.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS:
- iTeos: GALAXIES Lung-201 did not meet criteria for meaninful improvements in PFS
- iTeos Therapeutics Reports Q1 2025 Financial Results
- iTeos Therapeutics: Promising Clinical Developments and Financial Stability Drive Buy Rating
- iTeos Therapeutics price target lowered to $16 from $17 at Wells Fargo
- iTeos Therapeutics: Buy Rating Affirmed Amid Promising Pipeline and Strong Financial Position